Evidence map›Paper›PMID 42616269›Full record

ArticleClinical and experimental nephrology2026

Association of angiotensin receptor-neprilysin inhibitor therapy with changes in eGFR slope and home blood pressure in patients with chronic kidney disease.

Akio Namikawa, Yuko Shibuya, Daiki Yoshino, Dai Sato, Yoshitaka Furuto

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical and experimental nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Akio NamikawaDivision of Nephrology and Hypertension, NTT Medical Center Tokyo, 5-9-22 Higashi-Gotanda, Shinagawa-ku, Tokyo, 141-8625, Japan. akinmkw@gmail.com.ORCID http://orcid.org/0000-0001-5659-6606
Yuko ShibuyaDivision of Nephrology and Hypertension, NTT Medical Center Tokyo, 5-9-22 Higashi-Gotanda, Shinagawa-ku, Tokyo, 141-8625, Japan.
Daiki YoshinoDivision of Nephrology and Hypertension, NTT Medical Center Tokyo, 5-9-22 Higashi-Gotanda, Shinagawa-ku, Tokyo, 141-8625, Japan.
Dai SatoDivision of Nephrology and Hypertension, NTT Medical Center Tokyo, 5-9-22 Higashi-Gotanda, Shinagawa-ku, Tokyo, 141-8625, Japan.
Yoshitaka FurutoDivision of Nephrology and Hypertension, NTT Medical Center Tokyo, 5-9-22 Higashi-Gotanda, Shinagawa-ku, Tokyo, 141-8625, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEvidence regarding the renoprotective effects of angiotensin receptor-neprilysin inhibitor (ARNI) in patients with chronic kidney disease (CKD) remains limited. We investigated the association of ARNI initiation with changes in estimated glomerular filtration rate (eGFR) slope and home blood pressure in patients with non-dialysis CKD.

methodsThis retrospective single-center study included 89 patients with non-dialysis CKD who were switched from renin-angiotensin system inhibitors to sacubitril/valsartan because of insufficient blood pressure control. Changes in eGFR slope before and after ARNI initiation were evaluated using linear mixed-effects models. Associations between post-treatment home systolic blood pressure (post-HSBP) and eGFR slope were also assessed.

resultsMean age was 72 ± 11 years, and baseline eGFR was 29 ± 15 mL/min/1.73 m

conclusionsIn patients with non-dialysis CKD, ARNI initiation was associated with attenuation of eGFR decline and improved blood pressure control. Better home blood pressure control was associated with greater attenuation of eGFR decline. These findings support a potential role of ARNI as a treatment option for patients with CKD and insufficient blood pressure control despite RAS inhibitor therapy.

Indexed as

Angiotensin receptor–neprilysin inhibitorChronic kidney diseaseeGFR slopeHome blood pressureRenoprotection

Identifiers

PMID42616269

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.